Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Alumis is initially focused on developing two Tyrosine Kinase 2 (TYK2) inhibitors. Its most advanced candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of TYK2. The company plans to initiate Phase 3 pivotal trials of ESK-001 in moderate-to-severe plaque psoriasis in the 2H24. Its second candidate, A-005, is a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company initiated a Phase 1 program of A-005 in healthy volunteers in April 2024, and expects to report initial results by the end of the year.
The South San Francisco, CA-based company was founded in 2021 and plans to list on the Nasdaq under the symbol ALMS. Alumis filed confidentially on April 11, 2024. Morgan Stanley, Leerink Partners, Cantor Fitzgerald, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
